Repository logo

90K/LGALS3BP expression is upregulated in COVID-19 but may not restrict SARS-CoV-2 infection.

Published version

Repository DOI

Change log


Bosquillon de Jarcy, Laure 
Akbil, Bengisu 
Mhlekude, Baxolele 
Leyens, Johanna 
Postmus, Dylan 


Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP, displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Its antiviral potential in SARS-CoV-2 infection remains largely unknown. Here, we analyzed the expression of 90K/LGALS3BP in 44 hospitalized COVID-19 patients at multiple levels. We quantified 90K protein concentrations in serum and PBMCs as well as LGALS3BP mRNA levels. Complementary, we analyzed two single cell RNA-sequencing datasets for expression of LGALS3BP in respiratory specimens and PBMCs from COVID-19 patients. Finally, we analyzed the potential of 90K to interfere with SARS-CoV-2 infection of HEK293T/ACE2, Calu-3 and Caco-2 cells using authentic virus. 90K protein serum concentrations were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties in vitro.


Acknowledgements: B.A. and F.P. are supported by the Charité PhD programme. We thank all participants who took part in NAKO and the staff in this research program.

Funder: Berlin Institute of Health; doi:

Funder: Charité - Universitätsmedizin Berlin (3093)


90K, COVID-19, Interferon, LGALS3BP, SARS-CoV-2, Humans, Animals, Mice, COVID-19, Caco-2 Cells, HEK293 Cells, Leukocytes, Mononuclear, SARS-CoV-2, Antiviral Agents, RNA, Messenger, Antigens, Neoplasm, Biomarkers, Tumor

Journal Title

Clin Exp Med

Conference Name

Journal ISSN


Volume Title



Springer Science and Business Media LLC
Bundesministerium für Bildung und Forschung (01ER1301A/B/C)
Deutsche Forschungsgemeinschaft (158989968)